Rapid Therapeutic Science Laboratories (RTSL) 10-K 30 Mar 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 30, 2023	Jun. 30, 2022
Details
Registrant CIK	0001575659
Fiscal Year End	--12-31
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	000-55018
Entity Registrant Name	Rapid Therapeutic Science Laboratories, Inc.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	46-2111820
Entity Address, Address Line One	5580 Peterson Lane, Suite 120
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75201
City Area Code	800
Local Phone Number	497-6059
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 5,472,000
Entity Common Stock, Shares Outstanding		7,881,567
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Auditor Name	PWR CPA, LLP
Auditor Firm ID	6686
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 0	$ 192,484
Inventory, net	175,047	175,047
Prepaid expenses	58,146	51,631
Total current assets	233,193	419,162
Property and equipment:
Property and equipment, gross	1,564,503	1,214,917
Accumulated depreciation	(53,327)	(29,355)
Net property and equipment	1,511,176	1,185,562
Other long-term assets
Operating lease right-of-use asset, net	340,136	425,171
Sublicense agreement, net	170,075	170,075
Total assets	2,254,580	2,199,970
Current liabilities
Accounts payableand accrued liabilities, net	891,408	465,204
Notes payable - related party	820,602	283,700
Notes payable - other	2,481,333	1,099,734
Accrued interest payable	124,736	45,696
Current portion of operating lease obligation	98,509	73,289
Warrant liability	508,593	1,085,360
Derivative liability	40,647	0
Total current liabilities	4,965,828	3,052,983
Long-term liabilities
Convertible notes payable	150,000	150,000
Long-term portion of operating lease obligation	280,235	378,744
Total liabilities	5,396,063	3,581,727
Stockholders' deficit
Preferred stock value	0	0
Common stock value	7,763	7,743
Additional paid in capital	7,504,242	7,469,262
Accumulated deficit	(10,316,149)	(8,521,423)
Treasury stock	(337,339)	(337,339)
Total stockholders' deficit	(3,141,483)	(1,381,757)
Total liabilities and stockholders' deficit	$ 2,254,580	$ 2,199,970

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred Stock, Par or Stated Value Per Share	$ 0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	800,000,000	800,000,000
Common Stock, Shares, Outstanding	7,764,594	7,744,254
Series A Preferred Stock
Preferred Stock, Shares Authorized	16,500,000
Series B Preferred Stock
Preferred Stock, Shares Authorized	2,000,000
Series C Preferred Stock
Preferred Stock, Shares Authorized	8,500,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations
Revenues	$ 0	$ 534
Cost of goods sold	0	200
Gross profit	0	334
Operating expenses
General and administrative	1,239,361	2,141,632
Amortization expense	0	12,500
Depreciation expense	23,972	22,100
Total operating expenses	1,263,333	2,176,232
Other income (expense)
Gain (loss) on valuation of warrant liability	1,364,257	631,853
Interest expense	(1,895,650)	(1,323,838)
Total other income (expense)	(531,393)	(691,985)
Net loss before income taxes	(1,794,726)	(2,867,883)
Income taxes	0	0
Net income (loss)	$ (1,794,726)	$ (2,867,883)
Net loss per share, basic and diluted	$ (0.23)	$ (0.38)
Weighted average shares outstanding, basic and diluted	7,746,943	7,629,572

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock, Common	Total
Equity Balance at Dec. 31, 2020	$ 7,237	$ 5,972,445	$ (5,653,540)	$ (337,339)	$ (11,197)
Equity Balance, Shares at Dec. 31, 2020	7,239,042
Stock issued for conversion of debt, value	$ 444	889,587	0	0	890,031
Stock issued for conversion of debt, shares	443,783
Stock issued for accrued interest and lending fees, value	$ 1	2,291	0	0	2,292
Stock issued for accrued interest and lending fees, shares	929
Sale of common stock, value	$ 59	584,941	0	0	585,000
Sale of common stock, shares	58,500
Share-based compensation, value	$ 2	19,998	0	0	20,000
Share-based compensation, shares issued	2,000
Net income (loss)	$ 0	0	(2,867,883)	0	(2,867,883)
Equity Balance at Dec. 31, 2021	$ 7,743	7,469,262	(8,521,423)	(337,339)	(1,381,757)
Equity Balance, Shares at Dec. 31, 2021	7,744,254
Stock issued for conversion of debt, value	$ 16	14,984	0	0	15,000
Stock issued for conversion of debt, shares	16,340
Share-based compensation, value	$ 4	19,996	0	0	20,000
Share-based compensation, shares issued	4,000
Net income (loss)	$ 0	0	(1,794,726)	0	(1,794,726)
Equity Balance at Dec. 31, 2022	$ 7,763	$ 7,504,242	$ (10,316,149)	$ (337,339)	$ (3,141,483)
Equity Balance, Shares at Dec. 31, 2022	7,764,594

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net income (loss)	$ (1,794,726)	$ (2,867,883)
Adjustments to reconcile net loss to net cash provided by (used in) operations
Gain (loss) on valuation of warrant liability	(1,364,257)	(631,853)
Debt discount amortization and noncash interest	1,763,258	1,147,865
Stock-based compensation expense	20,000	20,000
Amortization of sublicense fees	0	12,500
Depreciation expense	23,972	22,100
Changes in operating assets and liabilities
Increase (decrease) in other current assets	(6,515)	(39,876)
Increase (decrease) in accounts payable and accrued liabilities	127,519	103,444
Increase (decrease) in Accrued interest payable	79,040	24,572
Increase (decrease) in other current liabilities	0	0
Net cash flows used in operating activities	(1,151,709)	(2,209,131)
Cash flows from investing activities
Additions to property and equipment	(39,155)	(292,531)
Net cash flows used in investing activities	(39,155)	(292,531)
Cash flows from financing activities
Private offering of common stock	0	585,000
Proceeds from convertible debt	0	1,650,000
Proceeds from notes payable - related party	536,902	260,000
Proceeds from notes payable - other	749,378	0
Payments of notes payable - other	(287,900)	(300,000)
Net cash flows provided by financing activities	998,380	2,195,000
Net decrease in cash and cash equivalents	(192,484)	(306,662)
Cash and cash equivalents at beginning of period	192,484	499,146
Cash and cash equivalents at end of period	0	192,484
Supplemental cash flow data
Cash paid for interest	55,619	0
Cash paid for income taxes	0	0
Non-Cash financing activities
Convertible notes and accrued interest converted to common stock	15,000	(892,323)
Accounts payable for acquisition of equipment	310,431	315,646
Operating lease obligation	$ 0	$ 446,429

General Organization and Busine

General Organization and Business	12 Months Ended
	Dec. 31, 2022
Notes
General Organization and Business	(1) General Organization and Business The Company we our Company Impact of COVID-19 Pandemic on Consolidated Financial Statements COVID-19

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Basis of Accounting - Principles of Consolidation Reverse Stock Split Cash and Cash Equivalents Inventory Property and Equipment Intangible Assets Revenue recognition FASB Revenue from Contracts with Customers (Topic 606) Earnings per Share Income Taxes Use of Estimates Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates. Fair Value of Financial Instruments Level 1: The preferred inputs to valuation efforts are “ quoted prices in active markets for identical assets or liabilities Level 2: FASB acknowledged that active markets for identical assets and liabilities are relatively uncommon and, even when they do exist, they may be too thin to provide reliable information. To deal with this shortage of direct data, the board provided a second level of inputs that can be applied in three situations. Level 3: If inputs from levels 1 and 2 are not available, FASB acknowledges that fair value measures of many assets and liabilities are less precise. The board describes Level 3 inputs as “ unobservable for situations in which there is little, if any, market activity for the asset or liability at the measurement date observable inputs Recently Issued Accounting Pronouncements Subsequent Events

Going Concern Disclosure

Going Concern Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Going Concern Disclosure	(3) Going Concern The Company’s consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has generated minimal revenues and has suffered recurring losses totaling $10,316,149 since inception. These factors, among others, indicate that there is substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of this filing. In order to obtain the necessary capital to sustain operations, management’s plans include, among other things, the possibility of pursuing new equity sales and/or making additional debt borrowings. There can be no assurances, however, that the Company will be successful in obtaining such additional financing, or that such financing will be available on favorable terms, if at all. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the outcome of this uncertainty.

Intangible Assets Disclosure

Intangible Assets Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Intangible Assets Disclosure	(4) Intangible Assets The Company has acquired certain intangible asset rights to use the metered dose inhaler (MDI) developed by EM3 Methodologies, LLC (“ EM3 EM3 Exclusive License Effective November 15, 2019, we entered into a sublicense agreement (the “ TMDI Agreement TMDI Original EM3 Exclusive License Effective February 9, 2021, both the TMDI Agreement and the Original EM3 Exclusive License were effectively terminated by mutual agreement of all parties and EM3 agreed to provide the Company with a royalty-free, perpetual license to use the Desirick Procedure or any derivation thereof and its application and use on an exclusive basis in the states of Texas, California, Florida and Nevada (subject to pre-existing licensing rights which have been provided by EM3 in such jurisdictions), and on a non-exclusive basis throughout the rest of the world. During the term of the TMDI Agreement, we were required to reimburse TMDI for the initial two year license fee owed by TMDI to EM3 in the amount of $200,000. We partially satisfied this obligation by making an equipment purchase on behalf of EM3 in the amount of $135,000, and agreed to pay the remaining license fee of $65,000, either by making cash fee payments or by making cash purchases of certain supplies from EM3, within a 24-month period (for which, we had recorded a liability of $44,925 for the unpaid portion of this amount in accounts payable as of December 31, 2020). We had recorded the entire $200,000 license fee as an intangible asset and were amortizing such expense on a straight-line basis over a 24-month period at the rate of $25,000 per quarter. Pursuant to the termination of the two agreements on February 9, 2021, we no longer owe TMDI (or EM3) any license fees under either agreement (including, the accrued liability of $44,925). Effective in February 2021, the Company is accounting for the licenses as an indefinite life asset not subject to amortization, resulting in the remaining balance of $170,075 being subjected to impairment testing at least annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.

Prior Asset Acquisition Disclos

Prior Asset Acquisition Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Prior Asset Acquisition Disclosure	(5) Prior Asset Acquisition On November 16, 2020, the Company closed an Asset Purchase and Sales Agreement with Razor Jacket, LLC (“ Razor Jacket RJ Agreement The Company has accounted for this transaction as an acquisition of assets, pursuant to the provisions of Accounting Standards Codification (ASC) 805-50. Accordingly, we have accounted for each component of the purchase price as follows: • • • Razor Jacket was originally formed in July 2019 for the sole purpose of researching techniques for the extraction of isolates from raw hemp. We have not presented any pro forma disclosures relating to this acquisition in the notes to our financial statements because the transaction is deemed an asset acquisition.

Property and Equipment Disclosu

Property and Equipment Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Property and Equipment Disclosure	(6) Property and Equipment As of December 31, 2022 and 2021, the Company had the following balances of property and equipment: December 31, 2022 2021 Equipment purchased from Razor Jacket, LLC and awaiting installation in the Company’s new facilities in Addison, Texas $ 500,000 $ 500,000 Equipment located in the Company’s existing facilities in Addison, Texas 221,412 221,412 Leasehold improvements in progress at the Company’s new facilities in Addison, Texas 840,591 491,005 Leasehold improvements in the Company’s existing facilities in Addison, Texas 2,500 2,500 Total property and equipment 1,564,503 1,214,917 Less: Accumulated depreciation (53,327) (29,355) Net property and equipment $ 1,511,176 $ 1,185,562 Effective October 1, 2021, the Company entered into a lease agreement with a landlord to lease 8,566 square feet of commercial office building space located in Addison, Texas (see Note 8). As of December 31, 2022, the Company was in the process of building out this space, pending obtaining any necessary governmental approvals, with the intention of utilizing it as its corporate office as well as its aerosol filling laboratory and isolate manufacturing facility, beginning in early 2023, depending on funding and contractor availability. As of December 31, 2022, the Company had capitalized leasehold improvements in progress at the new location in the amount of $840,591, of which $310,431 had not been paid and is reflected in Accounts Payable as of that date. The equipment purchased from Razor Jacket, LLC in November 2020 has been shipped to the Company’s existing facilities near Dallas, Texas, where it is awaiting installation in the new location in Addison, Texas, referenced above (see Note 5).

Notes Payable Disclosure

Notes Payable Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Notes Payable Disclosure	(7) Notes Payable As of December 31, 2022 and 2021, the Company had the following note payable obligations: December 31, 2022 2021 Convertible debenture issued to an accredited investor on August 4, 2021, in principal amount of $1,941,176, original issue discount of 15%, convertible at option of investor into a total of 194,118 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. $ 1,941,176 $ 1,075,048 Convertible debenture issued to an accredited investor on May 31, 2022, in principal amount of $411,764, original issue discount of 15%, convertible at option of investor into a total of 41,176 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. 411,764 - Convertible promissory notes issued to an accredited investor on November 15, 2019, maturing in 5 years, accruing interest at 5% per annum, convertible into common stock at $1.25 per share. 150,000 150,000 Unsecured advances received from two officers beginning in May 2021 through December 2022, accruing interest at 1% per annum, payable on demand. 396,902 - 260,000 Other short term notes issued to various affiliates of the former owners of Power Blockchain for acquisition of Treasury Stock, computers and equipment, and working capital financing, at stated interest rates of 10%. Amended on November 15, 2019, to be convertible into common stock at $1.25 per share. 48,386 48,386 Promissory note issued to an independent director on January 28, 2022, accruing interest at approximately 18% per annum, currently past due nominal maturity. 400,000 - Promissory note issued to an institutional investor on March 8, 2022, accruing interest at approximately 8% per annum, due in one year, in default and partially converted as of December 31, 2022. 70,104 - Convertible note issued to an accredited investor on July 25, 2022, net of unamortized debt discount of $40,647 (see further discussion below). 33,603 - Total notes payable $ 3,451,935 $ 1,533,434 Future maturities of notes payable as of December 31, 2022, without taking into account the unamortized debt discount, are as follows: Year ending December 31, 2023 $ 3,342,582 Year ending December 31, 2024 150,000 $ 3,492,582 On August 4, 2021, the Company closed a short-term bridge loan with an institutional investor in the gross amount of $1,941,176. The closing of this bridge loan resulted in net proceeds to the Company of $1,650,000, after deducting the 15% original issue discount. The Company accreted such discount as a non-cash charge to interest expense over the original term of the loan, which was extended in May 2022, as further discussed below. Additionally, we granted the investor warrants to purchase a total of 194,118 shares of our common stock at an exercise price of $10.00 per share for a period of five years, which was extended by two years in May 2022, as further discussed below. The bridge loan is in the form of a debenture which is convertible into shares of the Company’s common stock at the lower of: (a) (b) The bridge loan was originally structured with a maturity date in May 2022, however, due to unforeseen delays experienced in the Company’s planned public offering of common stock on a national exchange, we were unable to repay or convert the note by that date. On May 31, 2022, we reached a formal agreement with the institutional investor to extend the maturity of our existing Convertible Debenture in the amount of $1,941,176, until the earlier of (i) the completion of a qualified offering, (ii) an uplisting on a national exchange, or (iii) September 1, 2022, and simultaneously issued a new Convertible Debenture to the institutional investor payable for additional borrowings in the gross amount of $411,764, on substantially equivalent terms. The note is past due its nominal maturity date, however, the lender has not declared it to be in default. As a result of the formal extension agreement reached with the institutional investor in May 2022, we restructured our specific obligations to this investor as follows: • • • • Following the issuance of the initial Convertible Debenture in August 2021, the Company early adopted the provisions of ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. We elected to apply this new accounting principle to the subject convertible borrowings using the modified retrospective method. Pursuant to the provisions of ASC 470-60-35-5 with regard to debt modifications, we have accounted for the extension of the maturity of the initial Convertible Debenture in May 2022, on a prospective basis and, therefore, did not adjust any previously recorded amounts. The two tranches of Common Stock Purchase Warrants that we have granted to the investor in August 2021 and May 2022, as well as a grant of warrants that we made in August 2021 to the placement agent for the bridge loan to purchase a total of 9,706 shares of our common stock at an exercise price of $10.00 per share, with substantially similar terms, are subject to certain ownership limitations and adjustment provisions. These warrants also require the Company, at the holder’s option, following a Fundamental Transaction (as defined in the agreement), to purchase the warrants from the holder in cash, based on the Black Scholes value (as calculated pursuant to the terms of the warrant). As a result of this provision, the Company accounted for the issuance of the initial tranche of 203,824 warrants in August 2021 (including 9,706 shares to the placement agent) as a liability recorded at fair value in accordance with ASC 480-10. Using the Black Scholes model, the warrant liability was valued at issuance in the amount of $1,717,213 and was subsequently adjusted, as of December 31, 2021, to its then current fair value of $1,085,360. As of December 31, 2022, we adjusted the warrant liability to its current fair value of $140,615, based on the Black Scholes model, resulting in a gain on warrant liability of $944,745 that was recorded in our statement of operations for the year ended December 31, 2022. The Company has also accounted for the issuance of the additional tranche of 388,236 warrants in May 2022 as a liability recorded at fair value in accordance with ASC 480-10. Using the Black Scholes model, such warrant liability was valued at issuance in the amount of $756,285. This liability was recorded as a discount to the convertible debt of $350,000 with the excess $406,285 expensed as interest. The Company is accreting the debt discount, along with the original issue discount on the convertible debt, to interest expense over the term of the convertible debenture and such debt discount was fully accreted as of December 31, 2022. As of December 31, 2022, we adjusted the warrant liability to its current fair value of $367,978, based on the Black Scholes model, resulting in a gain on warrant liability of $419,512 that was recorded in our statement of operations for the year ended December 31, 2022. Prior to obtaining the bridge loan noted above, the Company received a series of unsecured cash advances from two of its officers beginning in May 2021 through December 2022, in the net amount of $396,902. These related party advances accrue interest at the rate of 1% per annum and are payable on demand. Such advances are expected to be repaid out of the proceeds of an underwritten public offering of the Company’s equity securities in conjunction with the planned listing on a national exchange. However, no assurance can be given that the Company will be successful in achieving a closing of the underwritten public offering. In January and March 2022, the Company closed two short-term loans from two different lenders in the total amount of $597,000. One of these loans was from an independent director of the Company in the amount of $400,000. Both loans were in the form of unsecured promissory notes bearing interest at rates of approximately 8-18% per annum with original maturities of one year. For the larger note with an independent director, the principal amount and accrued interest are due at the maturity date, which the director has agreed to extend to a date to be determined, whereas for the smaller note with an institutional investor, monthly payments of principal and interest of $21,276 were required beginning in May 2022. In the event of a default by the Company on the payment terms of either note, the notes would be convertible into shares of the Company’s common stock at a conversion price equal to the greater of (a) $0.001875 per share; and (b) 75% of the average closing bid price of the Company’s common stock, on the principal securities exchange or market where the Company’s common stock is then quoted or traded, for the five trading days immediately prior to the date of conversion. In December 2022, we defaulted on making the monthly note payment of $21,276 to the institutional investor due to our lack of liquidity which resulted in the investor electing to convert $15,000 of the note principal into 16,340 shares of our common stock, at a calculated conversion rate of $0.92 per share, leaving a remaining outstanding loan balance of $70,104, including default interest. In January and February 2023, the investor elected to convert an additional $44,856 of the note principal into a total of 116,973 shares of our common stock, at the applicable conversion rates at the time of each conversion, leaving a remaining outstanding loan balance of $25,248, including default interest (see Note 13). On July 25, 2022, the Company entered into an agreement with an accredited investor (the “ Buyer Note Effective March 31, 2021 and August 31, 2020, the Company reached the necessary milestones to trigger the conversion of certain notes payable issued on various dates in 2018 and 2019, as amended, into shares of the Company’s common stock, at conversion prices of $1.25 to $3.25 per share, subject to a 4.99% ownership limitation for each beneficial owner of such notes. In conjunction with these conversions, the holders of notes with total principal and accrued interest balances in the aggregate amount of $794,358 converted their notes into 433,203 shares of common stock, effective March 31, 2021, and the holders of notes with total principal and accrued interest balances in the aggregate amount of $501,137 converted their notes into 400,910 shares of common stock, effective August 31, 2020. As of December 31, 2022, convertible notes payable in the amount of $174,685, plus accrued interest in the amount of $48,624, remain outstanding and are available to be subsequently converted into 178,647 shares of common stock, subject to the ownership limitation (see Note 9). From June 30, 2020 to August 14, 2020, the Company entered into three identical Securities Purchase Agreements with an accredited investor (the “ Buyer Notes Effective November 15, 2019, the following transactions took place in the Company’s notes payable: • • • The Company performed an analysis of both the newly issued convertible notes and the newly amended existing notes, which were formerly non-convertible, to determine whether there was a beneficial conversion feature and noted none.

Long Term Lease Obligation Disc

Long Term Lease Obligation Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Long Term Lease Obligation Disclosure	(8) Long Term Lease Obligation Effective October 1, 2021, the Company entered into a lease agreement with a landlord to lease 8,566 square feet of commercial office building space located in Addison, Texas (see Note 6). The lease agreement is for a total term of 63 months, beginning October 1, 2021 and ending December 31, 2026. As of December 31, 2022, we are building out this space, pending obtaining any necessary governmental approvals, and intend to ultimately utilize it as our corporate office as well as our aerosol filling laboratory and isolate manufacturing facility. We are accounting for the lease agreement as an operating lease under ASU 2016-02, Leases (Topic 842). Accordingly, we have capitalized the present value of the future lease obligations and are amortizing the related right-of-use asset on a straight-line basis each month over the term of the lease. Due to our recent liquidity situation, we have been in arrears in the payment of the monthly rent, however, the landlord has not declared us to be in default of the lease agreement. Therefore, we have reflected such unpaid amounts in accounts payable as of December 31, 2022. Future operating lease minimum payments, together with their present values as of December 31, 2022, are summarized as follows: Year ending December 31, 2023 $ 98,509 Year ending December 31, 2024 102,792 Year ending December 31, 2025 107,075 Year ending December 31, 2026 111,358 Total future minimum lease payments 419,734 Less amounts representing interest (40,990) Present value of lease liability 378,744 Current portion of operating lease liability (98,509) Long-term portion of operating lease liability $ 280,235 As of December 31, 2022, the operating lease right-of-use asset and operating lease liabilities were $340,136 and $378,744, respectively. The long-term portion of the operating lease liabilities, $280,235, is included in long-term obligations. As of December 31, 2022, the weighted-average discount rate for this operating lease was 5%. The future operating lease payments are guaranteed by an employee of the Company.

Stockholders' Equity Disclosure

Stockholders' Equity Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Stockholders' Equity Disclosure	(9) Stockholders’ Equity Effective January 13, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “ Certificate of Amendment Effective April 1, 2022, the Company granted a common stock purchase warrant to a Washington, DC based firm that it has engaged to provide consulting services relating to certain federal regulatory matters. The warrant will enable the firm to purchase up to 360,000 shares of the Company’s common stock at an exercise price of $10.00 per share, or the lower of any public offering related conversion price, for a period of 10 years. The warrant is structured to be exercisable in six separate tranches of from 160,000 shares to 40,000 shares, assuming specified performance milestones are met by the firm for each tranche. Using the Black Scholes model, the Company has calculated the grant date value of this warrant to be $2,368,440. The Company will amortize this amount as stock compensation expense when the Company determines it is probable that that each performance milestone will be met. As of December 31, 2022, the Company has not recognized any stock compensation expense applicable to such warrant. On February 11, 2022, the Company issued a total of 4,000 shares of common stock to the two principals of a private company as compensation for arranging a contingent purchase of lab equipment from them. The Company valued such shares at $5.00 per share resulting in recognizing non-cash compensation expense in the nine months ended September 30, 2022 in the amount of $20,000. Under the agreement with the principals of the private company, the Company may complete the purchase of the lab equipment at a later date by making a cash payment to them of $52,000 or, alternatively, the Company may elect to return the equipment to them. In either case, however, the two principals will retain the 4,000 shares of common stock as compensation. During the year ended December 30, 2021, the Company entered into private stock subscription agreements with several accredited investors whereby it sold them a total of 58,500 shares of restricted common stock at an offering price of $10.00 per share, resulting in gross proceeds to the Company of $585,000. The investors also received an equal number of warrants to purchase additional shares of common stock at exercise prices of $21.25 to $25.00 per share. Such purchases must be made within 180 days of the Company’s 3-day volume weighted average stock price being above the exercise price, otherwise, such warrants are void. Effective March 31, 2021 and August 31, 2020, the Company reached the necessary milestones to trigger the conversion of certain notes payable issued on various dates in 2018 and 2019, as amended, into shares of the Company’s common stock, at conversion prices of $1.25 to $3.25 per share, subject to a 4.99% ownership limitation for each beneficial owner of such notes. In conjunction with these conversions, the holders of notes with total principal and accrued interest balances in the aggregate amount of $794,358 converted their notes into 433,203 shares of common stock, effective March 31, 2021, and the holders of notes with total principal and accrued interest balances in the aggregate amount of $501,137 converted their notes into 400,910 shares of common stock, effective August 31, 2020. As of December 31, 2022, convertible notes payable in the amount of $174,685, plus accrued interest in the amount of $48,624, remain outstanding and are available to be subsequently converted into 178,647 shares of common stock, subject to the ownership limitation (see Note 7). On December 29, 2020, the Board of Directors adopted, subject to the ratification by the majority shareholders, which ratification occurred pursuant to a majority shareholder consent, effective on December 30, 2020, the Rapid Therapeutic Science Laboratories, Inc. 2020 Equity Incentive Plan. Effective on January 7, 2022, the Board of Directors adopted, subject to the ratification by the majority shareholders, which ratification occurred pursuant to a majority shareholder consent, effective on January 11, 2022, the First Amended and Restated Rapid Therapeutic Science Laboratories, Inc. 2020 Equity Incentive Plan (the “ 2020 Plan The 2020 Plan provides an opportunity for any employee, officer, director or consultant of the Company, subject to limitations provided by federal or state securities laws, to receive (i) incentive stock options (to eligible employees only); (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v) shares in performance of services; (vi) other stock-based awards; or (vii) any combination of the foregoing. In making such determinations, the Board of Directors may take into account the nature of the services rendered by such person, his or her present and potential contribution to the Company’s success, and such other factors as the Board of Directors in its discretion shall deem relevant. Subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the 2020 Plan is the sum of (i) 1,000,000 shares, and (ii) an annual increase on March 1st of each calendar year, beginning in 2022 and ending in 2030, in each case subject to the approval of the Board of Directors or the compensation committee of the Company (if any) on or prior to the applicable date, equal to the lesser of (A) five percent (5%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; (B) 1,000,000 shares of common stock; and (C) such smaller number of shares as determined by the Board of Directors or compensation committee of the of the Company (if any)(the “ Share Limit The maximum number of shares subject to awards granted during a single calendar year to any non-employee director, taken together with any cash fees paid during the compensation year to the non-employee director, in respect of the director’s service as a member of the Board during such year (including service as a member or chair of any committees of the Board), will not exceed $500,000 in total value (calculating the value of any such awards based on the grant date fair value of such awards for financial reporting purposes). Compensation will count towards this limit for the calendar year in which it was granted or earned, and not later when distributed, in the event it is deferred. Employees, non-employee directors, and consultants of the Company and its subsidiaries are eligible to participate in the 2020 Plan. Incentive stock options may be granted under the 2020 Plan only to employees of the Company and its affiliates. Employees, directors and consultants of the Company and its affiliates are eligible to receive all other types of awards under the 2020 Plan. No awards are issuable by the Company under the 2020 Plan (a) in connection with services associated with the offer or sale of securities in a capital-raising transaction; or (b) where the services directly or indirectly promote or maintain a market for the Company’s securities. The 2020 Plan will automatically terminate on the 10th anniversary of original approval date of the Plan (December 29, 2030). However, prior to that date, the Company’s Board of Directors may amend or terminate the 2020 Plan as it deems advisable, but it cannot adopt an amendment if it would (1) without a grantee’s consent, materially and adversely affect that grantee’s award; or (2) without shareholder approval, increase the number of shares of the Company’s common stock that can be awarded under the 2020 Plan, except as provided for therein. The Company has made no awards under the 2020 Plan to date. In March 2018, the Board approved the establishment of a 2018 Stock Option Plan with an authorization for the issuance of up to 800,000 shares of common stock. The Plan is designed to provide for future discretionary grants of stock options, stock awards and stock unit awards to key employees and non-employee directors. The Company has made no awards under the 2018 Stock Option Plan to date.

Related Party Transactions Disc

Related Party Transactions Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Related Party Transactions Disclosure	(10) Related Party Transactions Office services were provided without charge by our Chief Executive Officer and director, Donal R. Schmidt, Jr., from November 15, 2019 to June 30, 2021, at which time, the Company relocated to a new leased office location through December 31, 2021. Pending completion of the build out of the new office and lab space in Addison, Texas (see Note 6), the Company relocated back to the office space in Dallas, Texas, provided by the Company’s Chief Executive Officer, as of January 1, 2022, under an arrangement whereby the Company is responsible for a relatively small share of office costs during its occupancy but has no long-term financial commitment. The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company’s audit committee is tasked with resolving related party conflicts.

Provision for Income Taxes, Dis

Provision for Income Taxes, Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Provision for Income Taxes, Disclosure	(11) Provision for Income Taxes The Company accounts for income taxes under FASB Accounting Standard Codification ASC 740 “ Income Taxes Components of net deferred tax assets, including a valuation allowance, as of December 31, 2022 and 2021, are as follows: December 31, 2022 2021 Deferred tax assets Net operating loss carryforward $ 1,147,000 $ 1,170,000 Total deferred assets 1,147,000 1,170,000 Valuation allowance (1,147,000) (1,170,000) Net deferred tax assets $ - $ - In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of December 31, 2022. The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences are as follows: Year Ended December 31, 2022 2021 U.S. federal statutory tax rate 21.0% 21.0% Valuation allowance (21.0)% (21.0)% Net effective tax rate 0% 0% At December 31, 2022, we had an unused net operating loss carryover of approximating $5,430,000, after taking certain non-deductible and non-taxable items into account, that is available to offset future taxable income which expires beginning 2038. The availability of such net operating loss carryover to be offset against any future taxable income is significantly limited as a result of a change of control transaction that occurred in November 2019. All prior tax years remain open currently.

Commitments and Contingencies,

Commitments and Contingencies, Disclosure	12 Months Ended
	Dec. 31, 2022
Notes
Commitments and Contingencies, Disclosure	(12) Commitments and Contingencies From time to time in the ordinary course of our business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We currently have no insurance policies covering such potential losses. We are not at this time involved in any legal proceedings.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes
Subsequent Events	(13) Subsequent Events As disclosed in Note 8, we defaulted in December 2022 on making the monthly note payment owed on a promissory note payable to an institutional investor due to our lack of liquidity, which resulted in the investor electing the available conversion option as a default remedy. In addition to the initial partial conversion that the investor elected to make in December 2022, the investor elected to make additional conversions in January and February 2023 in the amount of $44,856 of the note principal into a total of 116,973 shares of our common stock, at the applicable conversion rates at the time of each conversion. As a result of these additional issuances, we presently have a total of 7,881,567 shares of our common stock outstanding. In February 2023, the Company closed a short-term loan with an institutional investor in the gross amount $54,250. The closing of this loan resulted in net proceeds to the Company of approximately $50,000, after deducting the original issue discount and transaction fees. The Note has a maturity date of one year after the date of issuance and bears interest at a rate of 9% per annum, which is not due until maturity. At the option of the Buyer, the Note may be converted into shares of the Company’s common stock at a conversion price equal to the greater of (a) $0.000075 per share; and (b) 65% of the average closing bid price of the Company’s common stock, on the principal securities exchange or market where the Company’s common stock is then quoted or traded, for the three (3) lowest trading prices during the fifteen (15) Trading Day period ending on the latest complete trading day prior to the conversion date. Pursuant to the provisions of the 2020 Equity Incentive Plan (see Note 9), the Company’s Board of Directors approved an increase in the total number of shares authorized under the Plan, effective March 1, 2023, in the amount of 388,152 shares, which is equal to 5% of the total number of shares outstanding at the beginning of the year.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies: Basis of Accounting Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Basis of Accounting Policy	Basis of Accounting -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies: Principles of Consolidation, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Principles of Consolidation, Policy	Principles of Consolidation

Summary of Significant Accoun_4

Summary of Significant Accounting Policies: Reverse Stock Split Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Reverse Stock Split Policy	Reverse Stock Split

Summary of Significant Accoun_5

Summary of Significant Accounting Policies: Cash and Cash Equivalents Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Cash and Cash Equivalents Policy	Cash and Cash Equivalents

Summary of Significant Accoun_6

Summary of Significant Accounting Policies: Inventory, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Inventory, Policy	Inventory

Summary of Significant Accoun_7

Summary of Significant Accounting Policies: Property and Equipment, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Property and Equipment, Policy	Property and Equipment

Summary of Significant Accoun_8

Summary of Significant Accounting Policies: Intangible Assets, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Intangible Assets, Policy	Intangible Assets

Summary of Significant Accoun_9

Summary of Significant Accounting Policies: Revenue Recognition, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Revenue Recognition, Policy	Revenue recognition FASB Revenue from Contracts with Customers (Topic 606)

Summary of Significant Accou_10

Summary of Significant Accounting Policies: Earnings per share, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Earnings per share, Policy	Earnings per Share

Summary of Significant Accou_11

Summary of Significant Accounting Policies: Income Taxes, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Income Taxes, Policy	Income Taxes

Summary of Significant Accou_12

Summary of Significant Accounting Policies: Use of Estimates, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Use of Estimates, Policy	Use of Estimates Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates.

Summary of Significant Accou_13

Summary of Significant Accounting Policies: Fair value of financial instruments, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Fair value of financial instruments, Policy	Fair Value of Financial Instruments Level 1: The preferred inputs to valuation efforts are “ quoted prices in active markets for identical assets or liabilities Level 2: FASB acknowledged that active markets for identical assets and liabilities are relatively uncommon and, even when they do exist, they may be too thin to provide reliable information. To deal with this shortage of direct data, the board provided a second level of inputs that can be applied in three situations. Level 3: If inputs from levels 1 and 2 are not available, FASB acknowledges that fair value measures of many assets and liabilities are less precise. The board describes Level 3 inputs as “ unobservable for situations in which there is little, if any, market activity for the asset or liability at the measurement date observable inputs

Summary of Significant Accou_14

Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements

Summary of Significant Accou_15

Summary of Significant Accounting Policies: Subsequent Events, Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Policies
Subsequent Events, Policy	Subsequent Events

Property and Equipment Disclo_2

Property and Equipment Disclosure: Schedule of Property and Equipment Balances (Tables)	12 Months Ended
	Dec. 31, 2022
Tables/Schedules
Schedule of Property and Equipment Balances	December 31, 2022 2021 Equipment purchased from Razor Jacket, LLC and awaiting installation in the Company’s new facilities in Addison, Texas $ 500,000 $ 500,000 Equipment located in the Company’s existing facilities in Addison, Texas 221,412 221,412 Leasehold improvements in progress at the Company’s new facilities in Addison, Texas 840,591 491,005 Leasehold improvements in the Company’s existing facilities in Addison, Texas 2,500 2,500 Total property and equipment 1,564,503 1,214,917 Less: Accumulated depreciation (53,327) (29,355) Net property and equipment $ 1,511,176 $ 1,185,562

Notes Payable Disclosure_ Sched

Notes Payable Disclosure: Schedule of long-term debt obligations (Tables)	12 Months Ended
	Dec. 31, 2022
Tables/Schedules
Schedule of long-term debt obligations	December 31, 2022 2021 Convertible debenture issued to an accredited investor on August 4, 2021, in principal amount of $1,941,176, original issue discount of 15%, convertible at option of investor into a total of 194,118 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. $ 1,941,176 $ 1,075,048 Convertible debenture issued to an accredited investor on May 31, 2022, in principal amount of $411,764, original issue discount of 15%, convertible at option of investor into a total of 41,176 shares of common stock at $10.00 per share, payable upon earlier of a qualified offering, uplisting on national exchange, convertible at 25% discount to the price per share of common stock in a qualified offering, past due nominal maturity. 411,764 - Convertible promissory notes issued to an accredited investor on November 15, 2019, maturing in 5 years, accruing interest at 5% per annum, convertible into common stock at $1.25 per share. 150,000 150,000 Unsecured advances received from two officers beginning in May 2021 through December 2022, accruing interest at 1% per annum, payable on demand. 396,902 - 260,000 Other short term notes issued to various affiliates of the former owners of Power Blockchain for acquisition of Treasury Stock, computers and equipment, and working capital financing, at stated interest rates of 10%. Amended on November 15, 2019, to be convertible into common stock at $1.25 per share. 48,386 48,386 Promissory note issued to an independent director on January 28, 2022, accruing interest at approximately 18% per annum, currently past due nominal maturity. 400,000 - Promissory note issued to an institutional investor on March 8, 2022, accruing interest at approximately 8% per annum, due in one year, in default and partially converted as of December 31, 2022. 70,104 - Convertible note issued to an accredited investor on July 25, 2022, net of unamortized debt discount of $40,647 (see further discussion below). 33,603 - Total notes payable $ 3,451,935 $ 1,533,434

Notes Payable Disclosure_ Futur

Notes Payable Disclosure: Future maturities of notes payable (Tables)	12 Months Ended
	Dec. 31, 2022
Tables/Schedules
Future maturities of notes payable	Year ending December 31, 2023 $ 3,342,582 Year ending December 31, 2024 150,000 $ 3,492,582

Long Term Lease Obligation Di_2

Long Term Lease Obligation Disclosure: Future operating lease minimum payments (Tables)	12 Months Ended
	Dec. 31, 2022
Tables/Schedules
Future operating lease minimum payments	Year ending December 31, 2023 $ 98,509 Year ending December 31, 2024 102,792 Year ending December 31, 2025 107,075 Year ending December 31, 2026 111,358 Total future minimum lease payments 419,734 Less amounts representing interest (40,990) Present value of lease liability 378,744 Current portion of operating lease liability (98,509) Long-term portion of operating lease liability $ 280,235

Provision for Income Taxes, D_2

Provision for Income Taxes, Disclosure: Components of net deferred tax assets, including a valuation allowance (Tables)	12 Months Ended
	Dec. 31, 2022
Tables/Schedules
Components of net deferred tax assets, including a valuation allowance	December 31, 2022 2021 Deferred tax assets Net operating loss carryforward $ 1,147,000 $ 1,170,000 Total deferred assets 1,147,000 1,170,000 Valuation allowance (1,147,000) (1,170,000) Net deferred tax assets $ - $ -

Provision for Income Taxes, D_3

Provision for Income Taxes, Disclosure: Sources and tax effects of the differences (Tables)	12 Months Ended
	Dec. 31, 2022
Tables/Schedules
Sources and tax effects of the differences	Year Ended December 31, 2022 2021 U.S. federal statutory tax rate 21.0% 21.0% Valuation allowance (21.0)% (21.0)% Net effective tax rate 0% 0%

Summary of Significant Accou_16

Summary of Significant Accounting Policies: Reverse Stock Split Policy (Details) - shares shares in Millions	Mar. 31, 2022	Jan. 13, 2020
Details
Common stock authorized, increase	800	750

Going Concern Disclosure (Detai

Going Concern Disclosure (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Details
Accumulated deficit	$ 10,316,149	$ 8,521,423

Intangible Assets Disclosure (D

Intangible Assets Disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Additions to property and equipment	$ 39,155	$ 292,531
Sublicense agreement, net	170,075	$ 170,075
Sublicense agreement with Texas MDI
Stock issued in acquisition of assets, shares			5,600,000
Stock issued in acquisition of assets, value			$ 140,000
Total purchase amount of intangible asset			200,000
Additions to property and equipment			$ 135,000
Accrued liabilities, net				$ 44,925
Sublicense agreement, gross				$ 200,000
Sublicense agreement, net	$ 170,075

Prior Asset Acquisition Discl_2

Prior Asset Acquisition Disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
General and administrative	$ 1,239,361	$ 2,141,632
Asset Purchase and Sales Agreement with Razor Jacket, Cash Paid
Cash paid for acquisition			$ 300,000
Shares issued for acquisition			25,000
Shares issuable for acquisition			16,500,000
General and administrative			$ 300,000
Asset Purchase and Sales Agreement with Razor Jacket, Stock Issued
Stock issued in acquisition of assets, shares			25,000
Contingent consideration approved in acquisition of assets, shares			16,500,000

Property and Equipment Disclo_3

Property and Equipment Disclosure: Schedule of Property and Equipment Balances (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property and equipment, gross	$ 1,564,503	$ 1,214,917
Accumulated depreciation	(53,327)	(29,355)
Net property and equipment	1,511,176	1,185,562
Equipment purchased from Razor Jacket
Property and equipment, gross	500,000	500,000
Equipment located in the Company's facilities
Property and equipment, gross	221,412	221,412
Leasehold improvements in progress at new facilities
Property and equipment, gross	840,591	491,005
Leasehold improvements in the Company's facilities
Property and equipment, gross	$ 2,500	$ 2,500

Property and Equipment Disclo_4

Property and Equipment Disclosure (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Accounts payableand accrued liabilities, net	$ 891,408	$ 465,204
Commercial lease at new facilities
Capitalized leasehold improvements	840,591
Accounts payableand accrued liabilities, net	$ 310,431

Notes Payable Disclosure_ Sch_2

Notes Payable Disclosure: Schedule of long-term debt obligations (Details) - USD ($)	Feb. 28, 2023	Dec. 31, 2022	Dec. 31, 2021
Convertible debt payable		$ 3,451,935	$ 1,533,434
Convertible debenture issued to an accredited investor, Aug 4 2021
Convertible debt payable		1,941,176	1,075,048
Convertible debenture issued to an accredited investor on May 31, 2022
Convertible debt payable		411,764
Convertible promissory notes issued to two accredited investors, Nov 15 2019
Convertible debt payable		150,000	150,000
Unsecured advances received from two officers
Convertible debt payable		396,902	260,000
Other short term notes issued to various affiliates
Convertible debt payable		48,386	$ 48,386
Promissory note issued to an independent director
Convertible debt payable		400,000
Promissory note issued to an institutional investor
Convertible debt payable	$ 25,248	70,104
Convertible note issued to accredited investor, July 25, 2022
Convertible debt payable		$ 33,603

Notes Payable Disclosure (Detai

Notes Payable Disclosure (Details) - USD ($)	2 Months Ended	3 Months Ended	12 Months Ended
	Feb. 28, 2023	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Issuance of convertible debenture payable			$ 0	$ 1,650,000
Warrant liability			508,593	1,085,360
Derivative liability			40,647	0
Gain (loss) on valuation of warrant liability			1,364,257	631,853
Convertible debt payable			3,451,935	1,533,434
Proceeds from notes payable - related party			536,902	260,000
Stock issued for conversion of debt, value			15,000	890,031
Accrued interest payable			$ 124,736	45,696
Convertible debenture issued to an accredited investor, Aug 4 2021
Debt amount, gross				1,941,176
Proceeds from Issuance of convertible debenture payable				$ 1,650,000
Original issue discount				15%
Warrants issued			194,118	194,118
Exercise price per share			$ 10	$ 10
Discount to offering price				25%
Convertible debt payable			$ 1,941,176	$ 1,075,048
Convertible debenture issued to an accredited investor on May 31, 2022
Debt amount, gross				$ 1,941,176
Proceeds from Issuance of convertible debenture payable			$ 411,764
Warrants issued			388,236
Exercise price per share			$ 10
Convertible debt payable			$ 411,764
Convertible debenture Placement Agent
Warrants issued				9,706
Exercise price per share				$ 10
Warrant liability				$ 1,085,360	$ 1,717,213
Convertible debenture Warrants issued
Derivative liability			140,615
Gain (loss) on valuation of warrant liability			$ 944,745
Convertible debt Warrants issued, additional tranche
Warrants issued			388,236
Warrant liability			$ 367,978
Gain (loss) on valuation of warrant liability			419,512
Unsecured advances received from two officers
Convertible debt payable			396,902	260,000
Two short-term loans, Jan and March 2022
Debt amount, gross			597,000
Loan was from an independent director
Proceeds from notes payable - related party			400,000
Jan and March loan, conversion1
Stock issued for conversion of debt, value			$ 15,000
Stock issued for conversion of debt, shares	116,973		16,340
Conversion price per share			$ 0.92
Promissory note issued to an institutional investor
Convertible debt payable	$ 25,248		$ 70,104
Jan and March loan, conversion2
Stock issued for conversion of debt, value	$ 44,856
Convertible note issued to accredited investor, July 25, 2022
Proceeds from Issuance of convertible debenture payable			74,250
Convertible debt payable			33,603
Various notes in 2018 and 2019
Stock issued for conversion of debt, value				$ 794,358	$ 501,137
Stock issued for conversion of debt, shares				433,203	400,910
Conversion price per share				$ 3.25
Convertible notes payable, gross			174,685
Accrued interest payable			$ 48,624
Convertible promissory notes, from June to Aug 2020
Proceeds from Issuance of convertible debenture payable					$ 125,000
Stock issued for conversion of debt, value					$ 35,000
Stock issued for conversion of debt, shares		10,581			3,213
Conversion price per share				$ 1.25
Promissory notes with two accredited investors
Proceeds from notes payable - related party						$ 300,000
Stock issued for conversion of debt, value						$ 2,034,760
Stock issued for conversion of debt, shares						626,080

Long Term Lease Obligation Di_3

Long Term Lease Obligation Disclosure: Future operating lease minimum payments (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Details
Due December 31, 2023	$ 98,509
Due December 31, 2024	102,792
Due December 31, 2025	107,075
Due December 31, 2026	111,358
Current portion of operating lease obligation	98,509	$ 73,289
Long-term portion of operating lease obligation	$ 280,235	$ 378,744

Long Term Lease Obligation Di_4

Long Term Lease Obligation Disclosure (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Details
Operating lease right-of-use asset, net	$ 340,136	$ 425,171
Operating lease obligation total	378,744
Long-term portion of operating lease obligation	$ 280,235	$ 378,744
Operating lease discount rate	5%

Stockholders' Equity Disclosu_2

Stockholders' Equity Disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 24, 2023	Mar. 31, 2022	Jan. 13, 2020
Common stock authorized, increase					800,000,000	750,000,000
Preferred stock share, increase					100,000,000
Stock-based compensation expense	$ 20,000	$ 20,000
Sale of common stock, value		585,000
Stock issued for conversion of debt, value	15,000	890,031
Accrued interest payable	124,736	$ 45,696
Various notes in 2018 and 2019
Conversion price per share		$ 3.25
Stock issued for conversion of debt, value		$ 794,358	$ 501,137
Stock issued for conversion of debt, shares		433,203	400,910
Convertible notes payable, gross	174,685
Accrued interest payable	$ 48,624
Common stock purchase agreement, consulting services
Warrants issued, other	360,000
Exercise price per share	$ 10
Derivative liabilities	$ 2,368,440
Compensation for a contingent purchase of lab equipment
Share-based compensation, shares issued	4,000
Stock-based compensation expense	$ 20,000
private stock subscription agreements with various accredited investors
Sale of common stock, shares		58,500
Price per share sold	$ 10
Sale of common stock, value		$ 585,000
2020 Equity Incentive Plan
Common stock authorized under Stock Option Plan	10,000,000			388,152
2018 Stock Option Plan
Common stock authorized under Stock Option Plan	800,000
Series A Preferred Stock
Preferred Stock, Shares Authorized	16,500,000
Series B Preferred Stock
Preferred Stock, Shares Authorized	2,000,000
Series C Preferred Stock
Preferred Stock, Shares Authorized	8,500,000

Provision for Income Taxes, D_4

Provision for Income Taxes, Disclosure: Components of net deferred tax assets, including a valuation allowance (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Details
Net operating loss carry forward for deferred tax assets	$ 1,147,000	$ 1,170,000
Total deferred assets	1,147,000	1,170,000
Valuation allowance	(1,147,000)	(1,170,000)
Net deferred tax assets	$ 0	$ 0

Provision for Income Taxes, D_5

Provision for Income Taxes, Disclosure: Sources and tax effects of the differences (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Details
U.S. federal statutory tax rate	21%	21%
Valuation allowance, percentage	(21.00%)	(21.00%)
Net effective tax rate	0%	0%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	2 Months Ended	3 Months Ended	12 Months Ended
	Feb. 28, 2023	Mar. 24, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 30, 2023
Stock issued for conversion of debt, value			$ 15,000	$ 890,031
Entity Common Stock, Shares Outstanding					7,881,567
Proceeds from notes payable - other			$ 749,378	$ 0
2020 Equity Incentive Plan
Common stock authorized under Stock Option Plan		388,152	10,000,000
Jan and March loan, conversion2
Stock issued for conversion of debt, value	$ 44,856
Jan and March loan, conversion1
Stock issued for conversion of debt, value			$ 15,000
Stock issued for conversion of debt, shares	116,973		16,340
Short-term loan with an institutional investor, Feb 2023
Proceeds from notes payable - other		$ 50,000